Screening for Prostate Cancer: A Double-Edged Sword

Phillips, Barbara A.
May 2011
Internal Medicine Alert;5/15/2011, Vol. 33 Issue 9, p65
In this article, the author discusses the ineffectiveness of prostate cancer screening and controlled clinical trial in preventing mortality from such disease.


Related Articles

  • Jury still out on PSA testing. Cameron, Amanda // New Zealand Doctor;4/22/2009, p23 

    The article discusses the divided opinion over the value of prostate cancer screening in the wake of the recently concluded Prostate, Lung, Colorectal and Ovarian Screening Trial (PLCO) and the European Randomized Study of Screening for Prostate Cancer trial. The two trials were published in the...

  • RESULTS OF THE FIRST SCREENING ROUND IN THE FINNISH RANDOMISED TRIAL FOR PROSTATE CANCER. Määttonen, L.; Auvinen, A.; Tammela, T.; Stenman, U.; Aro, J.; Juuselo, H.; Hakarna, M. // Journal of Epidemiology & Community Health;Aug2004 Supplement 1, Vol. 58, pA95 

    The article presents information about a study, conducted to assess the feasibility of a large scale randomized trial by intermediate indicators of outcome after the first screening round of the trial for prostate cancer. In 1996-1999, during the first screening round 80458 men 55-47 years of...

  • Response. Crawford, E. David // JNCI: Journal of the National Cancer Institute;2/6/2008, Vol. 100 Issue 3, p223 

    The author comments on the responses generated from his review on the interval screening of prostate cancer. The author believes that Allain Braillon is mistaken in believing that his editorial was an advertising slogan. He agrees with Monique J. Roobol and Fritz H. Schröder in their claim...

  • The development of a web- and a print-based decision aid for prostate cancer screening. Dorfman, Caroline S.; Williams, Randi M.; Kassan, Elisabeth C.; Red, Sara N.; Dawson, David L.; Tuong, William; Parker, Elizabeth R.; Ohene-Frempong, Janet; Davis, Kimberly M.; Krist, Alexander H.; Woolf, Steven H.; Schwartz, Marc D.; Fishman, Mary B.; Cole, Carmella; Taylor, Kathryn L. // BMC Medical Informatics & Decision Making;2010, Vol. 10 Issue 1, p12 

    Background: Whether early detection and treatment of prostate cancer (PCa) will reduce disease-related mortality remains uncertain. As a result, tools are needed to facilitate informed decision making. While there have been several decision aids (DAs) developed and tested, very few have included...

  • PSA screening and prostate cancer mortality. Perron, Linda; Moore, Lynne; Bairati, Isabelle; Bernard, Paul-Marie; Meyer, François // CMAJ: Canadian Medical Association Journal;3/5/2002, Vol. 166 Issue 5, p586 

    Background Physicians have speculated that prostate-specific antigen (PSA) screening may be responsible for the reduction in prostate cancer mortality observed in the late 1990s. In order to test this hypothesis, we assessed the relation between the change in prostate cancer incidence in the...

  • New Trial Data Do Not End the PSA Screening Debate. Vastag, Brian // JNCI: Journal of the National Cancer Institute;6/16/2009, Vol. 101 Issue 12, p844 

    The article focuses on the conflicting results of trials made on the mortality benefit of prostate-specific antigen (PSA) on prostate cancer. It states that cancer screening trials conducted by the Prostate, Lung, Colorectal, and Ovarian (PLCO) and the European Randomized Study of Screening for...

  • Screening for Prostate Cancer. Lee, Thomas H.; Kantoff, Philip W.; McNaughton-Collins, Mary F. // New England Journal of Medicine;3/26/2009, Vol. 360 Issue 13, pe18 

    The article informs the readers of a video of a roundtable discussion in which oncologist Philip Kantoff and primary care physician Mary McNaughton-Collins debate the clinical implications of two randomized trials that examined the effect of annual prostate-specific-antigen (PSA) screening on...

  • Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests. Baker, Stuart G.; Kramer, Barnett S. // Journal of Medical Screening;Mar2008, Vol. 15 Issue 1, p18 

    Objectives: When evaluating screening for the early detection of cancer, it is important to estimate both harms and benefits. One common harm is a false-positive (FP), which is a positive screening result, perhaps followed by an invasive test, with no cancer detected on the diagnostic work-up or...

  • Prostate Cancer Screening: an Update on New Approaches. Klein, Erica A. // Renal & Urology News;May2010, Vol. 9 Issue 5, p23 

    The article discusses the use of prostate specific antigen (PSA) screening to detect screen-detected cancer in the prostate gland. It presents two medical studies the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and the European Randomized Study of Screening for Prostate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics